Voyager Therapeutics, Inc.
NMS: VYGRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Voyager Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get VYGR Z-Score →About Voyager Therapeutics, Inc.
Healthcare
Biotechnology
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
📊 Fundamental Analysis
Voyager Therapeutics, Inc. demonstrates a profit margin of -296.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 144.3% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -48.3%, which indicates that capital utilization is currently under pressure.
At a current price of $3.74, VYGR currently sits at the 38th percentile of its 52-week range (Range: $2.65 - $5.55).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$222.90M
Trailing P/E
--
Forward P/E
-2.18
Beta (5Y)
1.38
52W High
$5.55
52W Low
$2.65
Avg Volume
743K
Day High
Day Low